OverviewChartNewsTraderScreen

UC WAR. CALL 09/25 NOT/  DE000HD952T1  /

gettex Zertifikate
11/15/2024  11:45:25 AM Chg.-0.0200 Bid11/15/2024 Ask11/15/2024 Underlying Strike price Expiration date Option type
0.1500EUR -11.76% 0.1500
Bid Size: 125,000		 0.1600
Ask Size: 125,000		 NOVARTIS N 105.00 CHF 9/17/2025 Call
TeleTrader 10/29 Novartis' Q2 EPS surge by 116% to $1.58
GlobeNewswire 7/30 Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
TeleTrader 7/18 Novartis Q2 EPS up 47% to $1.60
GlobeNewswire 7/8 Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
GlobeNewswire 6/26 As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire 6/13 Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
GlobeNewswire 5/29 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
GlobeNewswire 5/13 Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
TeleTrader 5/2 Novartis to acquire Mariana Oncology for $1.7B
TeleTrader 4/23 Novartis up 5% on upbeat guidance, earnings
TeleTrader 4/23 Novartis EPS up 28% to $1.31 in Q1
GlobeNewswire 4/16 Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
GlobeNewswire 4/11 Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Develo...
TeleTrader 4/11 Novartis launches offer for Morphosys at €68 per share
TeleTrader 4/9 Novartis to reduce workforce by 680 in Product Development
GlobeNewswire 3/14 IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
TeleTrader 3/12 Germany clears Novartis' MorphoSys $2.9B deal
GlobeNewswire 2/28 Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire 2/28 PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invas...
TeleTrader 2/5 Novartis to acquire MorphoSys for $2.9B
TeleTrader 1/31 Novartis net sales up 8% to $11.4B in Q4
GlobeNewswire 1/10 Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire 1/5 Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
GlobeNewswire 1/2 Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...
GlobeNewswire 12/21/2023 Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...